8,285 results on '"NILOTINIB"'
Search Results
2. Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
3. Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
4. Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
5. PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML (PEARL)
6. Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
7. Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
8. A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
9. A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)
10. De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE)
11. Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
12. Molecular Profiling of Advanced Soft-tissue Sarcomas (MULTISARC)
13. Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
14. Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (ALERTCML)
15. Asciminib Roll-over Study
16. Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
17. A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
18. Nilotinib With Radiation for High Risk Chordoma
19. Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (ENESTop)
20. Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTfreedom)
21. Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma
22. Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus)
23. Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
24. Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
25. The Drug Rediscovery Protocol (DRUP Trial) (DRUP)
26. Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
27. Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data.
28. A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer.
29. Nilotinib boosts the efficacy of anti-PDL1 therapy in colorectal cancer by restoring the expression of MHC-I.
30. Evaluation of in vivo pharmacokinetic study of the anti-cancer drug imatinib using silkworms as an animal model.
31. Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma.
32. Asciminib, a novel allosteric inhibitor of BCR‐ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance.
33. Nilotinib: Disrupting the MYC-MAX Heterocomplex.
34. Clinicopathologic features of pityriasis rosea‐like drug eruption secondary to imatinib: A case report and review of the literature.
35. Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia.
36. S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia.
37. Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a Bioinformatics Study.
38. Nilotinib boosts the efficacy of anti-PDL1 therapy in colorectal cancer by restoring the expression of MHC-I
39. Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score
40. Second-generation Tyrosine Kinase Inhibitors Nilotinib- and Dasatinib-induced Keratosis Pilaris: A Case Report and Review of the Literature
41. Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN)
42. 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (NAUT)
43. Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
44. Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
45. Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
46. Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
47. Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
48. TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study (TIKlet)
49. Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia.
50. Lycorine attenuated proliferation and induced apoptosis on imatinib-resistant K562 cell by inhibiting autophagy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.